A pharmaceutical composition comprising a compound having the structure of Formula I, a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof, and a pharmaceutically acceptable carrier, wherein, X is selected from the group consisting of O, S and NR 9; A is selected from (CH 2)eN(R 7)C N(R 8)(CH 2)f and CH 2 C NR 7, wherein e and f are independently 0 or 1, wherein each group is bonded from its left to rings substituted by R3 and R4; L is -[Cm n q]-, where m is 0 or 1, q is 0 or 1, n is 0-11, Z is a group or several groups -CR 10 - connected in the usual way; p is 0-8; R1 and R2 are independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, aryloxy, aryloxyalkyl, halo, haloalkoxy, haloalkyl, heterocycle, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, hydroxy, hydroxyalkoxy, hydroxyalkyl, (NRaRb)alkoxy, (NRaRb) Alkenyl, (NRaRb)alkyl, (NRaRb)carbonylalkenyl and (NRaRb)carbonylalkyl; R3 and R4 are independently selected from the group consisting of hydrogen, alkoxy, alkyl, halo, haloalkoxy, haloalkyl and hydroxy; R5 and R6 are independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, arylalkyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, Hydroxy, hydroxyalkyl, nitro and -NRcRd; R 7 and R 8 are independently selected from the group consisting of hydrogen and alkyl; R 9 is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkoxycarbonyl, aryl, heterocyclylalkyl, hydroxyalkyl and (NRaRb)alkyl; R 10 is selected from the group consisting of hydrogen, alkyl, alkoxy, aryloxy, alkenyloxy, nitro, halo, primary, secondary and tertiary amine; R 11 is -OH; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl and heterocyclylsulfonyl; Rc and Rd are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl. X is selected from the group consisting of O, S and NR 9; A is selected from (CH 2)eN(R 7)C N(R 8)(CH 2)f and CH 2 C NR 7, wherein e and f are independently 0 or 1, wherein each group is bonded from its left to rings substituted by R3 and R4; L is -[Cm n q]-, where m is 0 or 1, q is 0 or 1, n is 0-11, Z is a group or several groups -CR 10 - connected in the usual way; p is 0-8; R1 and R2 are independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, aryloxy, aryloxyalkyl, halo, haloalkoxy, haloalkyl, heterocycle, heterocyclylalkenyl, heterocyclylalkoxy, heterocyclylalkyl, heterocyclyloxyalkyl, hydroxy, hydroxyalkoxy, hydroxyalkyl, (NRaRb)alkoxy, (NRaRb) Alkenyl, (NRaRb)alkyl, (NRaRb)carbonylalkenyl and (NRaRb)carbonylalkyl; R3 and R4 are independently selected from the group consisting of hydrogen, alkoxy, alkyl, halo, haloalkoxy, haloalkyl and hydroxy; R5 and R6 are independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, aryloxy, arylalkyl, carboxy, cyano, halo, haloalkoxy, haloalkyl, Hydroxy, hydroxyalkyl, nitro and -NRcRd; R 7 and R 8 are independently selected from the group consisting of hydrogen and alkyl; R 9 is selected from the group consisting of hydrogen, alkenyl, alkoxyalkyl, alkyl, alkoxycarbonyl, aryl, heterocyclylalkyl, hydroxyalkyl and (NRaRb)alkyl; R 10 is selected from the group consisting of hydrogen, alkyl, alkoxy, aryloxy, alkenyloxy, nitro, halo, primary, secondary and tertiary amine; R 11 is -OH; Ra and Rb are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, haloalkylsulfonyl and heterocyclylsulfonyl; Rc and Rd are independently selected from the group consisting of hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl and heterocyclylalkyl.